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Runx2 contributes to the 
regenerative potential of the 
mammary epithelium
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Theresa Higgins2, Ian Rosewell3, James C. Neil4, Matthew J. Smalley5, Owen J. Sansom1, 
Joanna Morris4, Ewan R. Cameron4 & Karen Blyth1
Although best known for its role in bone development and associated structures the transcription 
factor RUNX2 is expressed in a wide range of lineages, including those of the mammary gland. 
Previous studies have indicated that Runx2 can regulate aspects of mammary cell function and 
influence the properties of cancer cells. In this study we investigate the role of Runx2 in the 
mammary stem/progenitor population and its relationship with WNT signalling. Results show that 
RUNX2 protein is differentially expressed throughout embryonic and adult development of the 
murine mammary gland with high levels of expression in mammary stem-cell enriched cultures. 
Importantly, functional analysis reveals a role for Runx2 in mammary stem/progenitor cell function 
in in vitro and in vivo regenerative assays. Furthermore, RUNX2 appears to be associated with WNT 
signalling in the mammary epithelium and is specifically upregulated in mouse models of WNT-driven 
breast cancer. Overall our studies reveal a novel function for Runx2 in regulating mammary epithelial 
cell regenerative potential, possibly acting as a downstream target of WNT signalling.
The Runx genes are foremost recognised for their essential roles in haematopoiesis (Runx1), osteogenesis 
(Runx2) and neurogenesis (Runx3); principally unveiled through genetic deletion models1. Strictly linked 
to their function as key lineage determinants, several studies have also uncovered a role for RUNX pro-
teins in stem cell biology in a variety of systems, from sea urchins to mammalian cells2,3. Furthermore, 
as with many genes critical for development, the RUNX genes are also involved in carcinogenesis, man-
ifesting properties consistent with both tumour suppressive and oncogenic roles depending on context4. 
A role for the RUNX genes in the regulation of mammary lineages5 and breast cancer6,7 is becoming 
apparent but to date Runx2 has garnered most attention8,9. Runx2 knockout mice exhibit complete lack 
of bone formation and die soon after birth due to a failure of ossification10,11. Runx2 is also expressed 
in various extra-skeletal tissues where its function is less well understood. In particular, RUNX2 expres-
sion was noted in the developing embryonic mammary buds11, however the early lethality of the Runx2 
knock-out model hindered any additional in vivo study. In support of a functional role, RUNX2 has been 
demonstrated to be expressed in normal mammary epithelial cells and participate in the regulation of 
mammary-specific genes in vitro12,13. Since then in vitro studies have suggested a putative oncogenic role 
for RUNX2 in breast cancer through promotion of invasive and metastatic behaviour8,14,15. The first in 
vivo model to investigate RUNX2 in the mammary epithelium was through the generation of a mam-
mary specific Runx2-transgenic mouse model16. Ectopic expression of Runx2 impaired normal develop-
ment in pubertal and lactating animals, resulting in delayed ductal elongation and inhibition of alveolar 
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differentiation during pregnancy16. Moreover supporting a putative tumour promoting role, enforced 
mammary expression induced hyperplasia and lesions resembling sporadic ductal carcinoma in situ in 
a proportion of aged animals. In a clinical setting, RUNX2 was found to be highly expressed in a small 
percentage of human breast cancers where expression correlates with triple-negative (ER-, PR-, HER2-) 
disease16. These studies were complemented in a recent paper where loss of Runx2 impaired pubertal 
ductal outgrowth and disrupted progenitor cell differentiation during pregnancy17.
Both approaches used so far for the study of RUNX2 in the mammary epithelium utilised the 
MMTV-promoter which predominantly targets the luminal compartment of the mammary gland. 
However previous studies have shown that Runx2 is enriched in the mammary basal population16,18, 
which is interestingly where mammary stem cells are thought to reside. Mammary stem cells (MaSC) 
are a poorly characterized population of the adult mammary gland which have the ability to differentiate 
into multiple mammary cell lineages and the capacity to self-renew in order to maintain a stable pool of 
tissue stem cells19,20. Identifying new regulators of mammary stem cell biology is of pivotal importance 
for a better understanding of mammary gland and breast cancer development21.
Here, we use a combination of in vitro and in vivo approaches identifying a potential new role for 
RUNX2 in the mammary stem/progenitor cell population. RUNX2 is highly expressed in the stem-cell 
enriched mammosphere culture and is required for mammosphere formation. Moreover, loss of Runx2 
impairs the regenerative potential of mammary epithelial cells in in vitro and in vivo assays. We also link 
RUNX2 expression to WNT signalling activation in normal mammary and breast cancer mouse models. 
Together, this study identifies RUNX2 as a novel regulator of regenerative potential in the mammary 
epithelium.
Results
RUNX2 expression is temporally regulated during mammary gland development. Using 
qRT-PCR analysis of primary murine tissue we have shown previously that Runx2 is differentially 
expressed during the physiological stages of the adult mammary gland, and that Runx2 transcript is spe-
cifically enriched in the basal lineage of the mammary epithelium8,16. We now extend these findings using 
immunohistochemistry to demonstrate that RUNX2 protein is expressed in the embryonic mammary 
bud at embryonic day E12 and absent in later embryonic stages (Supplementary Fig. 1A). Furthermore, 
in agreement with previous transcript analysis RUNX2 protein shows a dynamic expression pattern in 
the adult mouse with decreased expression during late pregnancy and lactation compared to virgin and 
late involution stages (Supplementary Fig. 1B).
Deletion of Runx2 impairs in vivo mammary regenerative potential. As Runx2 transcript 
expression was shown to be enriched in the basal lineage16,18, we sought to define its role in this com-
partment. To this end we generated a loss of function RUNX2 mouse model (Runx2fl/fl; Supplementary 
Fig. S2) targeted to the K14+ mammary lineage22 which is the first time Runx2 has been specifically 
analysed in this lineage. Assessment of K14-Cre:Runx2fl/fl mice revealed that mature virgin mammary 
glands were comparable with K14-Cre:Runx2wt/wt controls at the histological level (Fig.  1A,B) and also 
by cell population profiling using a conditional GFP (Z/EG) reporter allele23 (Fig. 1C–E). In particular 
flow cytometry analysis on mouse mammary epithelial cells (MMECs) extracted from mature virgins 
showed no difference in total GFP expression levels between K14-Cre:Runx2wt/wt and K14-Cre:Runx2fl/fl 
mice (Fig. 1C). Since K14+ cells have been shown to contribute to both luminal and basal compartments 
of the adult mammary gland24,25, GFP+ percentages were independently assessed in each population. 
No significant bias in either the basal or luminal populations was detectable (Fig. 1D,E). The lactating 
capability of K14-Cre:Runx2fl/fl dams was tested by weighing litters at 7 days of age. No difference in 
weight was found between pups nursed by K14-Cre:Runx2wt/wt and K14-Cre:Runx2fl/fl females showing 
that K14-Cre:Runx2fl/fl females undergo normal lactation and involution (Fig. 1F,G). Overall these results 
indicate that in vivo loss of Runx2 in the K14+ mammary population does not impair normal mammary 
development.
As the basal lineage is enriched for mammary stem cells20 and RUNX proteins are emerging as key 
regulators of stem cell biology in different systems2, we probed the capacity of Runx2-deleted cells for 
regenerative potential using the recognised method of transplantation into a cleared mammary fat pad26. 
MMECs were extracted from K14-Cre:Runx2fl/fl and K14-Cre:Runx2wt/wt mice bearing the Z/EG trans-
gene. GFP expression was then used as a reporter to enrich for Runx2-deleted cells through FACS puri-
fied basal GFP+ cells, which were then injected into the cleared fat pad of 3-week old recipient mice. 
qRT-PCR on the injected basal population showed a significant knock-down of Runx2 transcript in 
GFP-positive cells extracted from K14-Cre:Runx2fl/fl mice confirming in vivo deletion although it should 
be noted that some residual expression was observed (Fig. 2A). As expected, the GFP negative population 
showed no difference in Runx2 expression (Supplementary Fig. S3). After 6 weeks, epithelial duct trees 
were detectable in 70% of controls (7/10) and 40% of Runx2 knock-out transplants (4/10) (Fig. 2B,C). 
Significantly however, whilst the sorted cells had reduced Runx2 expression before transplant, all of the 
reconstituted glands had equivalent RUNX2 expression by immunohistochemistry whether derived from 
K14-Cre:Runx2fl/fl or K14-Cre:Runx2wt/wt donors (Fig. 2D). These data suggest selection against RUNX2 
deleted cells, strongly indicating an important role for Runx2 in mammary regeneration and adult stem/
progenitor cell function.
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Figure 1. Deletion of Runx2 using K14-Cre does not overtly alter normal mammary development.  
(A) Representative wholemounts (top panel) and histological sections (H&E, bottom panel) of mammary 
glands extracted from 12 week old virgin K14-Cre:Runxwt/wt and K14-Cre:Runx2fl/fl mice. (n ≥ 4 for each 
genotype). Scale bar represents 1 mm for wholemounts and 50 μ m for H&E. (B) Immunofluorescence 
of CK14 (red) and CK18 (yellow) on mammary glands extracted from K14-Cre:Runx2wt/wt and K14-
Cre:Runx2fl/fl mice. Glands were counterstained with DAPI (blue). Scale bar represents 20 μ m. Cre-mediated 
GFP expression, as analysed by FACS, on whole mammary epithelial cell preparations (C) and gated on 
CD24high/CD29high basal (D) and CD24high/CD29low luminal (E) populations. MMECs were isolated from 
12 week K14-Cre:Runx2wt/wt and K14-Cre:Runx2fl/fl mice. Data are expressed as % of GFP+ cells over total 
in the selected population (± SD); n ≥ 5 for each genotype. (F) Bar chart showing the weight of pups in 
grams from K14-Cre:Runx2wt/wt and K14-Cre:Runx2fl/fl dams. Litters (n ≥ 5) were normalized to 6 pups and 
were weighed 7 days after the start of lactation. Data are expressed as mean (± SD). (G) Representative 
histological sections of mammary glands from K14-Cre:Runxwt/wt and K14-Cre:Runx2fl/fl female mice 
harvested at selected timepoints. Scale bar represents 50 μ m.
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RUNX2 expression is enriched in mammosphere cultures. As RUNX2 expression was aug-
mented in the stem cell rich basal population, and Runx2-depleted basal cells were selected against dur-
ing the generation of new mammary glands in vivo, we decided to test the role of RUNX2 in mammary 
stem cells (MaSC) further. A widely accepted method of studying stem cells is the mammosphere assay 
in which cells are grown in serum-free medium under non-adherent and clonogenic conditions27. Several 
studies have shown a link between mammospheres and MaSC; in particular cleared fat pad injection of 
a single sphere is able to generate mammary outgrowth with high efficiency, indicating that enrichment 
for cells with high regenerative capability is achievable in this assay28. In addition the progenitor/stem 
cell content of mammospheres has been shown to increase with passage27. As a control, primary mouse 
mammary epithelial cells (MMECs) were grown in differentiating conditions as adherent 2D-cultures 
on plastic (hereafter referred to as 2D MMECs) with foetal calf serum (FCS) supplemented with addi-
tional growth factors (Insulin, EGF and Cholera toxin). RUNX2 expression was assessed in primary 
cells grown in differentiating conditions and those grown as primary and secondary mammospheres. 
Since mammosphere passaging has been shown to enrich for mammary cells with stem cell features27, 
this experiment allowed us to assess Runx2 in the MaSC selected population. Endogenous Runx2 was 
significantly enriched in primary mammospheres when compared to 2D MMECs (2D-MMECs vs pri-
mary, p < 0.05; Fig.  3A). Importantly further significant enrichment occurred during secondary mam-
mosphere formation (2D-MMECs vs secondary p < 0.0001; primary vs secondary, p < 0.05; Fig.  3A). 
Western blot analysis confirmed RUNX2 enrichment in primary mammospheres at the protein level 
(Fig. 3B). Immunocytochemistry of the mammospheres showed that high RUNX2 expression was detect-
able in a subgroup of cells, often observed at the centre of the spheres (Fig. 3C). Together these results 
indicate an association between elevated RUNX2 expression and mammary stem cell-enriched cultures.
The mammosphere-forming potential of HC11 cells is driven by RUNX2 expression. To 
investigate the function of RUNX2 in the mammary stem/progenitor population, HC11, an immortalized 
mouse mammary cell line with stem/progenitor features29, was used to generate RUNX2 overexpres-
sion models. Confirming our previous results on primary MMECs, endogenous Runx2 expression levels 
were found to be higher in HC11 cells grown as mammospheres compared to 2D cultures (Fig.  4A). 
Figure 2. Runx2 deleted cells have a reduced capacity for regenerative potential in vivo. (A) qRT-PCR 
for Runx2 on FACS-purified CD24high/CD29high GFP+ cells extracted from K14-Cre:Runx2wt/wt and K14-
Cre:Runx2fl/fl mice. Gene expression is shown as relative expression to Gapdh (mean ± SD of 3 replicate 
samples). *p < 0.03 (Unpaired t-test with Welch’s correction). (B) Examples of reconstituted glands harvested 
6 weeks-post transplantation from the two cohorts shown as wholemounts. Scale bars represent 1 mm.  
(C) Pie chart graphs depict percentage outgrowth per individual gland from cleared fat pad transplantation 
of MMECs extracted from K14-Cre:Runx2wt/wt (7/10 outgrowth) and K14-Cre:Runx2fl/fl mice (4/10 
outgrowth). 1000 FACS purified CD24high/CD29high GFP+ cells were transplanted into the cleared 4th 
inguinal fat pad of 3 week old CD1-nude mice. P = 0.187 when testing for a difference between the group-
medians (Permutation test). (D) Immunohistochemistry for RUNX2 on reconstituted glands from the two 
cohorts (K14-Cre:Runx2wt/wt and K14-Cre:Runx2fl/fl) showing comparable RUNX2 levels despite reduced 
levels at transplant. Scale bar represents 30 μ m.
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Runx2-overexpressing HC11 (HC11-Runx2) and control (HC11-CTR) lines were then generated and 
RUNX2 overexpression was confirmed by western blot (Fig.  4B). No difference in growth in 2D was 
detectable between HC11-CTR and HC11-Runx2 (Fig. 4C). However HC11-Runx2 cells had an increased 
mammosphere-forming capability compared to HC11-CTR (Fig. 4D, p < 0.0001) while the colony size 
was not affected. These results show that RUNX2 overexpression increases the mammosphere forming 
potential of HC11 cells.
Runx2 deletion impairs mammary regenerative potential in vitro. As HC11 cells had relatively 
high levels of endogenous Runx2, we took advantage of our K14-Cre:Runx2fl/fl model to assess if loss 
of RUNX2 in the mammary epithelium could impact the mammosphere-forming capability of freshly 
extracted MMECs. Primary MMECs were extracted from K14-Cre:Runx2fl/fl and K14-Cre:Runx2wt/wt mice 
and plated in non-adherent conditions. Loss of Runx2 resulted in a significant reduction in the number 
and size of primary (Fig. 5A,B) and secondary (Fig. 5C) mammospheres. qRT-PCR on RNA extracted 
from mammospheres confirmed Runx2 deletion in K14-Cre:Runx2fl/fl derived spheres while Runx1 levels 
were not affected (Supplementary Fig. S4). In vitro clonogenic assays are widely used as a surrogate to 
identify putative stem/progenitor cells30,31 therefore the self-renewal potential of Runx2 deleted cells was 
tested in colony-forming assays in Matrigel. Analogous with mammospheres, qRT-PCR on primary and 
secondary colonies grown from wild type mice showed that endogenous Runx2 is enriched in second-
ary colonies (Fig.  5D, p < 0.001). MMECs from K14-Cre:Runx2fl/fl and K14-Cre:Runx2wt/wt mice were 
then assessed in Matrigel colony-forming assays. MMECs extracted from K14-Cre:Runx2fl/fl mice formed 
fewer primary and secondary colonies when compared to controls (Fig. 5E–G) while the colony size was 
not affected (Supplementary Fig. S5). Runx2 deletion was confirmed by qRT-PCR on RNA extracted 
from primary Matrigel cultures (Supplementary Fig. S6A). Runx1 levels were not affected indicating the 
specificity of the targeted deletion approach (Supplementary Fig. S6B). These results indicate that Runx2 
expression in the K14+ lineage of the mammary epithelium is required to sustain the regenerative poten-
tial of MMECs in in vitro regenerative assays.
Runx2 is a potential mediator of WNT signalling in mammary stem cell-enriched cultures. The 
evidence detailed above strongly suggests that RUNX2 contributes to the regenerative potential of the 
mammary epithelium. Since WNT signalling has been shown to regulate mammary stem cells32 and 
several lines of evidence link Runx genes and WNT signalling in lower organism development and in 
Figure 3. RUNX2 expression is enriched during mammosphere culture. (A) qRT-PCR for Runx2 on 
mouse mammary epithelial cells grown in 2D (2D MMECs), primary and secondary mammospheres. 
Gene expression is shown as relative expression to Gapdh (mean ± SD). n ≥ 5 for each group. Expression in 
primary and secondary mammospheres was compared to 2D MMECs; *p < 0.05. **p < 0.0001 (ANOVA with 
post-hoc Bonferroni correction). Expression in primary mammospheres was also compared to secondary 
mammospheres; *p < 0.05 (ANOVA with post-hoc Bonferroni correction). (B) Western blot of MMECs 
grown in 2D and primary mammospheres from three independent experiments. GAPDH used as loading 
control. (C) Representative RUNX2 immunocytochemistry of primary and secondary mammospheres. Scale 
bars represent 30 μ m.
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osteogenesis33,34, the role of RUNX2 as a possible target or regulator of WNT signalling in mammary 
stem cells was investigated. The effect of WNT signalling on the mammosphere-forming capacity of 
MMECs was first tested. Treatment of primary MMECs grown as mammospheres with recombinant 
WNT3a resulted in an increase in mammosphere number and size compared to vehicle (Supplementary 
Fig. S7). These data confirm the growth promoting effect of WNT activation on a mammary stem cell 
enriched culture. Runx2 as a downstream target of WNT signalling in MMECs was tested by perform-
ing a 24 h treatment with recombinant WNT3a on MMECs grown as mammospheres. After incuba-
tion with the recombinant protein, qRT-PCR for Axin2 was used as an indicator of WNT pathway 
activation (Fig.  6A). WNT3a treatment caused significant up-regulation of Runx2 expression in mam-
mospheres (Fig. 6B) while levels of Slug, another transcription factor involved in mammary stem cells, 
were unchanged (Supplementary Fig. S8A), indicating a specific effect on Runx2. Moreover qRT-PCR for 
Hes1, one of the main transcriptional targets of the NOTCH signalling pathway, showed no difference 
in expression levels following WNT3a treatment, confirming specific activation of the WNT signalling 
pathway only (Supplementary Fig. S8B). These results point to Runx2 as a potential downstream target 
of WNT signalling in mammary stem cell-enriched cultures. Furthermore, we observed significant in 
vivo upregulation of RUNX2 (Fig. 6C,D) in the mammary epithelium of a mouse model of WNT acti-
vation where the pathway effector β -catenin has been specifically activated in the mouse mammary 
Figure 4. RUNX2 potentiates mammosphere-forming potential of HC11 cells. (A) qRT-PCR for Runx2 
on HC11 grown in 2D and as mammospheres (mammo). Gene expression is shown as relative expression 
to Gapdh (mean ± SD); n ≥ 3 for each group. Expression in mammospheres was compared to 2D MMECs; 
*p = 0.02 (Unpaired t-test with Welch’s correction). (B) Western blot of HC11 cells transfected with empty 
vector (HC11-CTR) and RUNX2 overexpressing plasmid (HC11-Runx2). GAPDH used as loading control. 
(C) Growth curve of HC11-CTR and HC11-Runx2 cells grown in 2D culture. Cell numbers were counted 
daily in triplicate for each time point, for each cell line. Data are expressed as mean + /− SD. Graph is 
representative of two independent experiments from 2 independent lines of HC11-CTR and 3 independent 
lines of HC11-Runx2. (D) Mammospheres from HC11-CTR and HC11-Runx2 cells grown in non-adherent 
conditions for 7 days. Data are expressed as mean + /− SD. Graph representative of four independent 
experiments from 2 independent lines of HC11-CTR and 3 independent lines of HC11-Runx2. The number 
of mammospheres formed by HC11-CTR and HC11-Runx2 was compared. *p < 0.0001 (Unpaired t-test with 
Welch’s correction).
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Figure 5. Deletion of RUNX2 impairs mammary epithelial cell regenerative potential. (A) Bright field 
images of mammosphere cultures derived from K14-Cre:Runx2wt/wt (top) and K14-Cre:Runx2fl/fl (bottom) 
female mice. Scale bars represent 100 μ m. Quantification and size of primary (B) and secondary (C) 
mammospheres on MMECs extracted from K14-Cre:Runx2wt/wt and K14-Cre:Runx2fl/fl mice. Primary and 
secondary mammospheres were counted and measured after 7 days in culture. Data are expressed as mean 
(± SD). Four independent experiments for each group. The number and size of mammospheres formed by 
K14-Cre:Runxwt/wt and K14-Cre:Runx2fl/fl MMECs was compared. *p < 0.01; **p < 0.001 (Unpaired t-test 
with Welch’s correction). (D) qRT-PCR for Runx2 on Matrigel colonies derived from wild type MMECs. 
Gene expression is shown as relative expression to Gapdh (mean ± SD; n = 4 for each group). *p < 0.001 
(Unpaired t-test with Welch’s correction). (E) Bright field images of primary Matrigel colonies derived from 
K14-Cre:Runx2wt/wt and K14-Cre:Runx2fl/fl mice. Scale bars represent 100 μ m. Quantification of primary 
(F) and secondary (G) Matrigel colonies from K14-Cre:Runx2wt/wt and K14-Cre:Runx2fl/fl MMECs. Primary 
and secondary Matrigel colonies were counted and measured after 7 days in culture. Data are expressed as 
mean number of colonies (% over the WT) ± SD. Four independent experiments for each group. *p < 0.001 
(Paired t-test).
www.nature.com/scientificreports/
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gland (BLG-Cre:Catnb+/lox(ex3) mice). Thus RUNX2 expression is increased as a result of WNT signalling 
activation in mammary stem cell-enriched cultures and in the mammary epithelium in vivo. Treatment 
with recombinant WNT3a also caused a significant induction of Runx2 in HC11 cells (Fig. 6E). To study 
the effects of loss of Runx2 in the context of WNT activation, siRNA was used to knock down Runx2 in 
Figure 6. RUNX2 contributes to activation of WNT signalling transcriptional program in mammary cells. 
qRT-PCR for Axin2 (A) and Runx2 (B) on primary mammospheres (1st Mammo) treated for 24h, with either 
vehicle (Vh) or recombinant WNT3a. 3 independent MMEC extractions for each group. *p < 0.05. **p < 0.0005 
(Unpaired t-test with Welch’s correction). Gene expression is shown as relative expression to Gapdh (mean ± SD). 
(C) qRT-PCR for Runx2 on RNA extracted from BLG-Cre:Catnb+/+ and BLG-Cre:Catnb+/lox(ex3) virgin glands. 
n ≥ 3 for each group. *p < 0.05 (Unpaired t-test with Welch’s correction). (D) RUNX2 immunohistochemistry on 
lactating day 1 glands from BLG-Cre:Catnb+/+ and BLG-Cre:Catnb+/lox(ex3) mice, scale bar represents 50 μ M.  
(E) qRT-PCR for Runx2 on RNA extracted from HC11 cells treated for 24 h, with either vehicle (Vh) or WNT3a. 
n = 5 for each group. *p = 0.01 (Paired t-test). Gene expression is shown as relative expression to Gapdh. Data 
are expressed as mean fold expression (± SD). (F,G) qRT-PCR for Axin2, CyclinD1 and Sox9 on RNA extracted 
from HC11 cells transfected with either scrambled (siSCR) or Runx2 targeted siRNA (siRunx2) and treated for 
24 h with WNT3a. n = 5 independent experiments for each group. *p < 0.05 **p < 0.005. (Paired t-test). Gene 
expression is shown as fold change relative to siSCR. Data for siRunx2 are expressed as mean fold expression 
(± SD).
www.nature.com/scientificreports/
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HC11 cells (Supplementary Fig. S9). After 24h treatment with recombinant WNT3a, RUNX2 silencing 
caused a significant reduction in the transcript levels of the WNT target Axin2 (Fig.  6F). In addition 
two other classic Wnt target genes, CyclinD1 and Sox9, showed a consistent reduction in transcript levels 
in RUNX2-silenced HC11 cells (Fig. 6G). We then examined the effects of the WNT3a ligand on mam-
mospheres derived from K14-Cre:Runx2fl/fl MMECs. Again WNT3a resulted in a significant increase in 
the size and number of mammospheres derived from control cells (Fig. 7). However although an increase 
in size and number was also observed in WNT3a treated K14-Cre:Runx2fl/fl mammospheres compared to 
non-treated K14-Cre:Runx2fl/fl cultures, treatment failed to completely rescue the deficit in these Runx2fl/fl  
cells. Together these results indicate that Runx2 is a downstream target that can modulate the outcome 
of WNT signalling.
RUNX2 is upregulated in mouse models of WNT-driven metaplastic breast cancer. WNT 
pathway activation has been linked to breast cancer, in particular to the triple negative subgroup, where it 
is associated with poor clinical outcome35. Similarly, RUNX2 is highly expressed in a small percentage of 
human breast cancers and its expression correlates with triple negative tumours16. To investigate whether 
the association between Wnt signalling activation and RUNX2 expression that we observed in normal 
mammary epithelium extend to a neoplastic setting, a panel of Wnt-induced and Wnt-independent 
mouse models representing different breast cancer subtypes36 was stained for RUNX2. Wnt-independent 
luminal-like models (MMTV-PyMT and MMTV-Her2) as well as a basal-like BRCA1 tumour model 
(BLG-Cre:Brca1fl/fl:p53+/–) showed low or negative RUNX2 staining (Fig.  8A). Conversely, in models 
where activation of the WNT pathway through APC deletion drives tumourigenesis (ie Apc1572T and 
BLG-Cre:Ptenfl/flApcfl/fl), high RUNX2 positivity was observed, especially in areas of squamous metaplasia 
Figure 7. Exogenous WNT activation does not rescue Runx2-depleted mammospheres. Bright field 
images of mammosphere cultures (A) derived from K14-Cre:Runx2wt/wt (top) and K14-Cre:Runx2fl/fl (bottom) 
mice, treated for 6 days with either vehicle (Vh) or recombinant WNT3a (100 ng/ml). Scale bars represent 
100 μ m. The average area of primary mammospheres (B) and number (area cut-off 4000 pixel) of primary 
spheres (C) of MMECs extracted from K14-Cre:Runx2wt/wt and K14-Cre:Runx2fl/fl mice, treated for 6 days 
with either vehicle (Vh) or WNT3a. Mammospheres were counted and measured after 6 days in culture. 
Data are expressed as mean (± SD). The area and number of mammospheres formed by K14-Cre:Runxwt/
wt and K14-Cre:Runx2fl/fl MMECs after WNT3a treatment was compared. *p < 0.05; **p < 0.001 (Unpaired 
t-test with Welch’s correction).
www.nature.com/scientificreports/
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(Fig.  8B). In the Apc1572T model in particular, RUNX2 expression was very high in the basal layer of 
the squamous metaplastic lesions (Supplementary Fig. S10) where a high percentage of Ki67+ cells has 
been shown to reside37. Thus RUNX2 expression is associated with WNT driven mouse models of breast 
cancer, confirming the link between activated WNT pathway and RUNX2 expression in normal and 
transformed mammary epithelium.
Discussion
Mammary stem cells represent a poorly characterized population of the adult mammary gland character-
ized by the ability to differentiate into the multiple cell lineages which make up the mammary epithelium, 
and the capacity to self-renew in order to maintain a stable pool of tissue stem cells21. Previous findings 
from our groups16,18,38 showed that Runx2 transcript expression is highest in the mammary basal popu-
lation, a lineage which is enriched in mammary stem cells19,20. Several proteins that are enriched in the 
basal population (such as SLUG, β 1-Integrin, LGR5) also play a role in the regulation of mammary stem 
cells31,39,40. Studies in diverse animal models indicate that RUNX proteins can act as key players in stem 
cell biology2,41. Runx genes are ideally placed for the control of stem cell homeostasis as they regulate 
transcription through interaction with a wide variety of co-repressors and co-activators and bring to this 
transcriptional network high flexibility and context dependency42—features necessary for the regulation 
of dynamic entities such as stem cells. Moreover RUNX transcription factors converge on different sig-
nalling pathways such as Wnt, Notch and Hedgehog, all key mediators of the stem cell state43.
To date, analysis of RUNX2 in the primary mammary epithelium has been limited to two in vivo 
studies, both which utilised MMTV-driven transgenes16,17. Here we have created an in vivo deletion 
model of Runx2 based on the K14-Cre system, previously shown to be useful in targeting the mammary 
basal lineage24. The K14-Cre:Runx2fl/fl mouse had no discernible phenotype during normal mammary 
development. However challenging stem cell capability through regeneration assays revealed an impor-
tant role for Runx2 and selection of cells retaining expression of RUNX2. It is possible that the RUNX2 
positive cell population, able to promote regeneration in glands grafted with mutant cells, could originate 
from basal cells characterized by inefficient K14-Cre recombinase activity44 where although the reporter 
has been activated there is incomplete deletion of Runx2. Furthermore, we have evidence of hemizygote 
deletion of Runx genes in other systems (ERC, pers comm) demonstrating that cells can experience Cre 
expression but fail to undergo homozygous deletion with a strong selection pressure to retain at least one 
allele of Runx. Although our results strongly support selection to retain RUNX2 it would be important 
Figure 8. RUNX2 is upregulated in murine models of Wnt-driven metaplastic breast cancer. RUNX2 
immunohistochemistry on mouse models of breast cancer. Representative examples of MMTV-PyMT, 
MMTV-Her2 and BLG-Cre:Brca1fl/flp53+/− (Wnt-independent tumour models; (A)) and also Apc1572T and 
BLG-Cre:Apcfl/flPtenfl/fl which are WNT-driven breast cancer models (B). Three to five independent tumours 
for each genotype were stained for RUNX2. Scale bars represent 50 μ M.
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to carry out limiting dilution transplantation assays to conclusively show RUNX2’s absolute requirement 
for stem cell potential in vivo.
Of note, our FACS analysis of the two main mammary populations showed there was no difference 
in the proportion of basal GFP+ cells between K14-Cre:Runx2fl/fl and K14-Cre:Runx2wt/wt. Perhaps as 
mammary stem cells constitute only a small proportion of the CD29hi CD24+ basal lineage (1/590)19 
then a decrease in such a small population may be too subtle to be detected using this combination of 
markers. Interestingly there was no defect in outgrowth when embryonic mammary buds from consti-
tutive Runx2 knockout mice were used17. These differences could be explained by the fact that we used 
adult basal mammary cells compared to embryonic mammary fragments. Since the relationship between 
embryonic and adult mammary stem cells has yet to be fully determined, we propose that embryonic 
mammary cells and adult mammary stem cells may represent very different entities where RUNX2 could 
play diverse and even contrasting roles. Supporting this view, a recent lineage tracing study showed 
that embryonically-derived, long label-retaining cells are restricted to the primary ducts near the nipple 
region, suggesting that embryonic mammary stem cells represents a subpopulation of the adult MaSC 
population45. Future studies based on lineage tracing are necessary to fully characterize the Runx2 pos-
itive population and clarify the precise contribution of RUNX2 positive cells to embryonic and adult 
mammary development and homeostasis. Of course we showed previously that Runx1 is also highly 
expressed in the mammary basal lineage and has a similar dynamic expression pattern during mammary 
development. Therefore we cannot rule out that there may be developmental redundancy between these 
genes in the mammary stem/progenitor cell explaining why K14-Cre:Runx2fl/fl glands appear unper-
turbed in vivo. Analysis of mammary epithelium in K14-Cre:Runx1fl/fl animals is not possible due to 
other developmental issues when deleting Runx1 in the K14+ lineage. However Runx1 levels did not 
increase during mammosphere culture (data not shown) and we did not see upregulation of Runx1 
when deleting Runx2 in mammospheres or Matrigel colonies (Figs S4 & S6). Nevertheless redundancy 
is an important consideration and we are actively pursuing the interplay and function of both genes in 
this lineage.
Our gene expression analysis on primary mouse cells provides additional evidence for a role of 
RUNX2 in mammary stem cells. Runx2 is enriched in mammosphere and 3D matrigel cultures, two 
widely used assays for the study of MaSC regenerative potential in vitro27,28,31,32,46. Furthermore, deletion 
of RUNX2 strongly impairs the colony forming capability of primary mammary cells when challenged 
in mammosphere and 3D Matrigel colony forming assays. The HC11 cell line is a useful in vitro model 
of murine mammary epithelial stem/progenitor cells and it has been shown that Runx2 levels decrease in 
HC11 cells during in vitro differentiation47. We have now shown that RUNX2 over-expression increases 
the mammosphere forming potential of HC11 cells while not affecting their growth in 2D. In support 
of our data Runx2 over-expression blocks HC11 differentiation17 suggesting that forced expression of 
RUNX2 maintains HC11 cells in a stem-like state.
Since Wnt signalling is a key regulator of MaSCs19,32 and Runx genes have been linked with Wnt 
signalling in sea urchin stem cell development and osteogenesis33,34,48 we investigated the role of Runx2 
as a possible mediator of Wnt signalling in mammary stem cell enriched cultures. First we showed 
that Wnt treatment of mammospheres induces Runx2 transcription indicating that Runx2 is a down-
stream target of Wnt signalling. The specificity of Runx2 activation was confirmed by examination of 
Slug, another gene involved in MaSC which did not show any change after Wnt treatment. Interestingly, 
Gaur et al. provide evidence for a direct interaction between WNT signalling downstream mediators 
and the Runx2 promoter showing that a functional TCF regulatory element responsive to canonical 
WNT signalling resides in the promoter of the Runx2 gene33. Runx2 expression was also increased in a 
mouse model where endogenous β -catenin is stabilized through the deletion of exon 3 of the β -catenin 
gene49 representing WNT pathway activation. These findings add further evidence supporting the link 
between Runx2 and Wnt signalling in vivo. Exogenous WNT3A was not able to rescue the mammosphere 
growth defects induced by loss of Runx2 suggesting that RUNX2 may be modulating the WNT signalling 
response. Supporting this hypothesis, we showed that loss of Runx2 impaired activation of Wnt target 
genes after Wnt activation in HC11 cells. Runx2 over-expression is sufficient to maintain HC11 cells in a 
less-differentiated state, potentially through inhibition of Notch1 activation17. Our data now suggest that 
Runx2 expression in MaSC may be important as part of the WNT mediated transcription program thus 
potentiating their regenerative potential while at the same time inhibiting Notch signalling and blocking 
their differentiation.
Markers which delineate mammary stem cells are synonymous with a cancer stem-cell population in 
WNT driven mammary tumours, and the gene expression profile of these cancer stem cells correlates 
with poor outcome in triple negative breast cancer50. It is therefore interesting that we find RUNX2 to 
be strongly expressed in WNT-driven mouse models of breast cancer. The WNT/β -catenin pathway is 
typically aligned with triple-negative breast cancer51 and it is tempting to speculate that the association 
of RUNX2 with this subtype16 may be due to its relationship with WNT signalling.
The development of squamous metaplasia in the mouse mammary gland is induced by aberrant WNT 
signalling49,52,53, which activates a process of trans-differentiation of the mammary epithelium resulting in 
epidermal-like structures with extensive keratinization and basosquamous/pilar histological structures37. 
Intriguingly, RUNX2 expression in the WNT-driven models of squamous metaplastic breast cancer was 
limited to the tumour cells positioned in the basal layer of the lesions. This compartment is characterized 
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by cells in a high proliferative state when compared with the other squamous part of the tumour which 
are mainly quiescent37. Moreover in the normal epidermis this is the compartment were the stem cell 
population resides54. These results further suggest a link between RUNX2 expression and a highly pro-
liferative population of squamous metaplasia, which could be endowed with cancer stem cell features.
The association between high RUNX2 expression, WNT pathway activation and WNT-induced squa-
mous metaplasia in mouse models seems to be conserved in human disease where transcriptomic anal-
ysis on human metaplastic breast cancer (MBC) listed RUNX2 within the upregulated gene signature55 
while WNT signalling was found to be activated in 95% of this disease type56. MBC is a heterogene-
ous subtype of triple-negative breast carcinoma characterized by poor outcome, and few therapeutic 
options57. Finally, of note is the finding that transcriptomic analysis showed high RUNX2 activity to 
characterize the ER-negative basal-like tumours6, while RUNX1 protein expression correlates with poor 
prognosis in the triple negative subgroup7. We envisage that future studies, using in vivo triple-negative 
breast cancer models will help to clarify the role of RUNX1 and RUNX2 in triple-negative breast cancer.
Methods
Animals. Animal work was carried out with ethical approval from University of Glasgow under the 
revised Animal (Scientific Procedures) Act 1986 and the EU Directive 2010/63/EU (PPL 60/4181). All 
experiments were performed in accordance with relevant guidelines and regulations. Animals were 
housed in individual ventilated cages in a barrier facility proactive in environmental enrichment. 
The generation and characterization of Runx2fl/fl conditional knock-out mice is described in detail in 
Supplementary Fig. S1. K14-Cre mice22 were obtained from The Jackson Laboratory (USA). The Z/EG, 
MMTV-PyMT, MMTV-Her2 and BLG-Cre/Brca1fl/fl/p53+/– mice have been described previously23,38,58,59. 
Apc1572T mouse tumour samples were kindly provided by Professor Riccardo Fodde. BLG-Cre/Ptenfl/fl/
Apcfl/fl mouse tumour samples and the Catnb+/lox(ex3) mouse model were kindly provided by OJ Sansom. 
FVB and CD1-nude mice were obtained from Charles River Research Models & Services (UK).
Fat pad transplantation. Basal cells sorted by flow cytometry (FACS) were suspended in PBS/50% 
Matrigel™ Matrix Phenol Red-Free (BD Biosciences, CAT 356237) and injected using a 10 μ l Hamilton 
syringe (Hamilton, CH) into the inguinal (4th gland) fat pads of 3-week-old CD1-nude females cleared of 
endogenous epithelium. Clearing of excised fat pads was confirmed using wholemount analysis.
Wholemount/histological analysis of mammary glands. For wholemount analysis, inguinal 
mammary glands were dissected, fixed in Carnoy’s (ethanol/chloroform/acetic acid), stained with car-
mine alum and captured with a Zeiss stereomicroscope. The state of pregnancy was determined by 
checking vaginal plugs, with day of plug taken as d0.5. For involution studies litters, standardised to 
6 pups, were culled to initiate forced involution 7 days after parturition and the dam was taken at the 
selected time points. For histological analysis, adult mammary glands were dissected into 10% neutral 
buffered formalin and processed for haematoxylin and eosin (H&E) staining. For histological analysis of 
embryonic mammary glands, whole embryos were fixed, cut transversally at the level of the 4th and 3rd 
mammary gland, embedded in paraffin blocks and serial sections were taken to identify the embryonic 
mammary tissue.
Preparation of primary mouse mammary cells. Mouse mammary epithelial cells (MMECs) were 
extracted from virgin mammary glands (females > 12 weeks of age) and at least 2 mice per group. Glands 
were dissected using a McIlwain tissue chopper (Mickle Laboratories, UK) and digested in Collagenase 
(300 U/ml)/Hyaluronidase (100 U/ml) solution (Sigma) at 37 °C. After digestion pellets were incubated 
for 5 min at RT in 2 ml NH4Cl solution (0.8% in H2O) to eliminate red blood cells and further digested 
in 2 ml of TEG (0.25% trypsin and 1 mM EGTA in PBS) plus 10% DNase and filtered through a 70 μ m 
mesh to eliminate remaining clumps then counted using Trypan blue exclusion. For 2D cultures, cells 
were seeded at 3 × 105 cells/well in 6-well plates and cultured in DMEM/F12/10% FCS with Pen/strep 
and L-Glut, supplemented with 10 ng/ml EGF (Sigma), 5 μ g/ml Insulin (Roche) and 10 ng/ml Cholera 
Toxin (Sigma). After 7 days 2D MMECs were dissociated enzymatically and processed for qRT-PCR.
Mammospheres. Cells were plated in ultra-low adherent 24-wells plates (Corning) at a density of 
20,000 viable cells/ml (primary mammospheres) or 5000 cells/ml (secondary mammospheres). Cells 
were grown in serum-free DMEM/F12 medium with Pen/Strep and L-Glut (Life Technologies), sup-
plemented with B27 (Invitrogen), 20 ng/ml EGF (Sigma), 20 ng/ml bFGF (Sigma), 0.4% BSA and 4 μ g/
ml Heparin (Sigma). Growth factors were re-added every 3–4 days. After 7 days, mammospheres were 
counted under a bright field microscope, collected by gentle centrifugation (800 rpm for 5 minutes) and 
dissociated enzymatically (10 min in TEG at 37 °C in water bath) and mechanically, by pipetting. The 
cells obtained from dissociation were checked for single-cellularity, counted using Trypan blue exclusion 
and re-seeded to generate secondary mammospheres. For qRT-PCR analysis, mammospheres were pro-
cessed after 7 days for RNA extraction. For histologic analysis mammospheres were fixed with 500 μ l 
of 2% PFA for 15 minutes. After centrifugation pellets were resuspendend in 150 μ l of 3% UltraPureTM 
low-melting agarose (Invitrogen) and left for 20 minutes at room temperature to solidify. The agarose 
plug was fixed in 70% ethanol and embedded in paraffin. RUNX2 staining was carried out using citrate 
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buffer antigen retrieval and standard IHC protocols. For size measurement primary and secondary mam-
mosphere colonies were photographed with a bright field microscope (Olympus CKX41) and colony size 
assessed using Axiovision software (Zeiss). Runx2fl/fl and Runx2wt/wt MMECs were spin-infected with 
Ad5CMVCre-eGFP (Iowa University) (3.30 hours at 300 g, RT; MOI = 100) in 200 μ l DMEM/F12 with 
2% FCS, 20 ng/ml EGF (Sigma) and 20 ng/ml bFGF (Sigma). After adenoviral infection, cells were seeded 
at 20,000 cells/ml in ultra-low adherent 24-wells plates (Corning) and counted after 7 days.
Matrigel colony forming assay. Cells extracted from 12 week virgin mice were resuspended in 
ice-cold Growth-factor-reduced Matrigel (BD Biosciences, CAT 356237). 8000 cells/well were seeded for 
primary Matrigel colony formation, 5000 cells/well were seeded for secondary Matrigel colony formation 
in 1 ml of DMEM/F12 with Pen/Strep and L-Glut supplemented with 20 ng/ml EGF (Sigma). Fresh EGF 
was added every 3–4 days. After 7 days, primary colonies were counted and dissociated enzymatically 
(10 min in TEG at 37 °C in water bath) and mechanically, and single cells re-seeded. qRT-PCR analysis 
and histologic analysis were performed as per mammospheres. Matrigel colonies were photographed 
with a bright field microscope and the colony size assessed using Axiovision software (Zeiss).
WNT3a treatment. Mammospheres were grown for 1 week in mammosphere media supplemented 
with 100 ng/ml of recombinant WNT3a (Sigma, SRP3259) or vehicle (H2O). Growth factors and WNT3a 
were re-added at 3–4 days. After 6 or 7 days of culture, mammospheres were visually counted under 
a bright field microscope or digitally counted using ImageJ on previously acquired bright field images. 
For short-term WNT3a treatment, mammospheres and 2D-MMECs were grown for 3 days in normal 
conditions and 100 ng/ml of recombinant WNT3a or vehicle (H2O) added for 24 hours.
Flow cytometry/cell sorting. Mammary glands were dissected from 12 week old virgin females (at 
least 3 groups of n ≥ 3 for Runx2fl/fl and Runx2wt/wt). Single cell suspensions of primary mammary epithe-
lial cells were labelled with CD24-Phycoerythrin (PE), CD29-PerCP-eFluor 710, CD31-Allophycocyanin 
(APC) and CD45-APC (BD Bioscience). Live Lin- cells (DAPI/CD31/CD45-negative) were gated using a 
BD FACSAria to assess GFP+ populations in CD24highCD29low (luminal) and CD24highCD29high popula-
tions (basal/myoepithelial) using FlowJo software. For cell sorting, CD24highCD29low and CD24highCD29high 
populations were collected and processed for RNA extraction and qRT-PCR. The efficacy of the sorting 
strategy was confirmed by qRT-PCR for a basal (CK5) and a luminal (CK18) marker (data not shown).
Cell lines. HC11 cells (kind gift of Dr. Torsten Stein) were grown in RPMI 1640, 10% FCS; 1% Pen/
strep and 1% L-Glutamine (all Life Technologies), Insulin (5 μ g/ml) and EGF (10 ng/ml). Cells were 
grown in a Galaxy+ incubator (RS Biotech) at 37 °C with 5% CO2. Cells were dissociated enzymatically 
and passaged using a solution of 0.05% trypsin (Gibco). To generate RUNX2 stable overexpression cell 
lines, HC11 cells were transfected with pBABE-Puro-Runx2 (HC11 Runx2) or empty vector pBABE-Puro 
(HC11 CTR) through electroporation using Nucleofector Kit V. After electroporation, cells were allowed 
to recover for 24 h and then selected in puromycin selection media (2 μ g/ml). To generate RUNX2 tran-
sient knock-out, HC11 cells were transfected with siRNA constructs Flexitube Gene Solution (Qiagen, 
GS12393) or Negative control siRNA (Qiagen, SI03650325) using the Amaxa Nucleofector protocol.
HC11 cell assays. Cells were seeded in triplicate in 12 well plates, harvested at 24, 48, 72 and 96 hours 
and counted using the CASY TT cell counter (Roche) for 2D growth. For mammosphere cultures, cells 
were dissociated enzymatically (Trypsin) and mechanically by pipetting to single-cell suspension and 
plated on non-adherent plates (Corning) at a concentration of 1000 cells/ml. Cells were grown in a 
serum-free RPMI 1640 with Pen/strep and L-Glut, supplemented with B27 (Invitrogen), 20 ng/ml EGF 
(Sigma), 20 ng/ml b-FGF (Sigma), BSA 0.4% and 4 μ g/ml Heparin (Sigma). Mammospheres were grown 
for 7 days and colonies counted under a bright field microscope.
Immunohistochemistry. Sections were incubated overnight at 4 °C with RUNX2 antibody (Sigma 
HPA022040, 1/100), incubated with Anti-rabbit secondary antibody (Dako EnVision) for 1 hour at RT, 
treated with DAB and counterstained with haematoxylin. Images were captured using a Zeiss AX10 or 
an Olympus BX51 microscope.
Immunofluorescence. Sections were incubated overnight at 4 °C with primary antibodies diluted 
in Dako REALTM Antibody Dilutent. Primary antibodies used were anti-cytokeratin 8/18 (Fitzgerald 
20R-CP004; 1/400), anti-GFP (Abcam ab6556; 1/250), anti-CK14 (Abcam ab7800; 1/250). Confocal 
images were captured using a Zeiss 710 confocal microscope.
Quantitative RT-PCR. RNA was isolated using RNeasy Mini Kit (Qiagen, Crawly, West Sussex, 
UK) according to the manufacturer’s instructions. RNA was reverse transcribed to cDNA using 
Quantitect® Reverse Transcription Kit (Qiagen, 205311). SYBR Green qRT-PCR was performed 
using SYBR® Green JumpstartTM Taq (Sigma, S4438) master mix. The following primers were used: 
mRunx1 (Qiagen Quantitect Assay QT0010000380), mRunx2 (Qiagen Quantitect assay QT00102193), 
mRunx3 (F-GCACC GGCAGAAGATAGAAGAC; R-GGTTTAAGAAGCCTTGGATTGG), 
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mAxin2 (F-GCTCCAG AAGATCAC AAAGAG; R-AGCTTTGAGCCTTCAGCATC), mHes1 
(F-CAGGAGGGAAAGGTTATTTTGACG; R-TAG TTGTTGAGATGGGAGACCAGGCG), mSlug 
(F-CTCACCTCGGGAGCATACA; R-GACTTAC ACGCC CCAAGGATG) and mGapdh (PrimerDesign 
kit). All reactions were performed in triplicate, and expression was normalised to Gapdh.
Western blot. Nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction 
Reagents (Thermo Scientific, Cat No 78833) as per kit instructions. At least 15 micrograms of pro-
tein extract were resolved on 10% NuPAGE Novex Bis-Tris gels (Life Technologies) and transferred 
to Hybond-ECL nitrocellulose membranes (Amersham). Membranes were probed with antibodies to 
RUNX2 (HPA022040, Sigma), GAPDH (Cell Signalling), Lamin A/C (Cell Signalling).
Statistical analysis. Statistical significance (p < 0.05) of differential findings between experimental 
groups was determined by a Student’s t-test (unless otherwise specified) using Minitab or GraphPad 
software.
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